At the 11th Annual New York Lung Cancer Symposium, held on November 12, 2016, in New York City, Roman Perez-Soler, MD, spoke about what is currently understood about resistance to EGFR-targeted therapies and how to treat this population of patients.
Speaking at the 11th Annual New York Lung Cancer Symposium, held on November 12, 2016, in New York City, Howard (Jack) West, MD, medical director of the thoracic oncology program at the Swedish Cancer Institute in Seattle, laid out the available treatment options for patients with treatment-naïve, EGFR-positive NCSLC cancer.
Today, we are speaking with Dr. Alexander Drilon, a medical oncologist at Memorial Sloan Kettering Cancer Center in New York City who specializes in treating patients with lung cancer. Dr. Drilon recently spoke at the New York Lung Cancer Symposium held on November 12th on three relatively new molecular drug targets for lung cancer.
The immune checkpoint antibody pembrolizumab (Keytruda, Merck) improved survival in previously treated advanced urothelial cancer compared to chemotherapy, according to the manufacturer of the immunotherapy.
Professor Mishra and his colleagues recently developed a program called Pipeline for Cancer Inference or PiCnIc for short that analyzes patient tumor sequencing data to create potential ways that the tumor may evolve and progress that is patient-personalized.
Combining venetoclax (Venclexta, AbbVie and Genentech) plus a tyrosine kinase inhibitor targeting the BCR-ABL oncogene can eradicate chronic myeloid leukemia stem cells in a mouse model of the disease.